<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="medicines are currently available. These include (i) the neuraminidase inhibitors" exact="oseltamivir" post="(Roche), zanamivir (GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate"/>
 <result pre="currently available. These include (i) the neuraminidase inhibitors oseltamivir (Roche)," exact="zanamivir" post="(GlaxoSmithKline), peramivir (BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo);"/>
 <result pre="These include (i) the neuraminidase inhibitors oseltamivir (Roche), zanamivir (GlaxoSmithKline)," exact="peramivir" post="(BioCryst Pharmaceuticals), and laninamivir octanoate (Daiichi Sankyo); (ii) the"/>
 <result pre="laninamivir octanoate (Daiichi Sankyo); (ii) the M2 ion channel blockers" exact="rimantadine" post="(Sun Pharma) and amantadine (Endo); (iii) favipiravir (Toyama Chemical),"/>
 <result pre="(ii) the M2 ion channel blockers rimantadine (Sun Pharma) and" exact="amantadine" post="(Endo); (iii) favipiravir (Toyama Chemical), which inhibits the ribonucleic"/>
 <result pre="called 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA, 1, Figure 1) [5,6,7,8,9,10,11,12,13]. EFdA is an" exact="adenosine" post="derivative armed with an ethynyl group at the 4′-position,"/>
 <result pre="Activities We intended to analyze the anti-influenza activity of 4′-ethynyl" exact="adenosine" post="derivatives, namely EFdA (1), 4′-ethynyl-2′-deoxyadenosine (EdA, 2) [13], and"/>
 <result pre="EFdA analogs may work against the influenza virus [25]. The" exact="adenosine" post="derivatives of compounds 1–3 were evaluated for their in"/>
 <result pre="Silyl–Hilbert–Johnson reaction between adenine and acetate 12 furnished the desired" exact="adenosine" post="derivative 13 in a 73% yield [33,34]. After the"/>
 <result pre="was treated with Bu3SnH and azobisisobutyronitrile (AIBN) to generate deoxy" exact="adenosine" post="derivative 16 in an 86% yield [35,36]. The deprotection"/>
 <result pre="to generate phosphate monoester. EdA (2) was easily hydrolyzed by" exact="adenosine" post="deaminase to generate the corresponding inactive inosine derivative [6,11,37]."/>
 <result pre="easily hydrolyzed by adenosine deaminase to generate the corresponding inactive" exact="inosine" post="derivative [6,11,37]. However, EdAP, which has the same scaffold"/>
 <result pre="cycloSal phosphate group could prevent the conversion of EdAP by" exact="adenosine" post="deaminase, or other unknown mechanisms may exist. 3. Materials"/>
 <result pre="resistant to 4′-ethynyl-2-fluoro-2′-deoxyadenosine: Comparative sequential passage study with lamivudine, tenofovir," exact="emtricitabine" post="and BMS-986001Antivir. Ther.20141917918910.3851/IMP269724162098 17.WuV.H.SmithR.A.MasoumS.RaugiD.N.BaS.SeydiM.GroblerJ.A.GottliebG.S.MK-8591 (4′-ethynyl-2-fluoro-2′-deoxyadenosine) exhibits potent activity against"/>
 <result pre="HIV-2 mutants in cultureAntimicrob. Agents Chemother.201761e00744-1710.1128/AAC.00744-1728559249 18.NjendaD.T.AralaguppeS.G.SinghK.RaoR.SönnerborgA.SarafianosS.G.NeogiU.Antiretroviral potency of 4′-ethnyl-2′-fluoro-2′-deoxyadenosine," exact="tenofovir" post="alafenamide and second-generation NNRTIs across diverse HIV-1 subtypesJ. Antimicrob."/>
 <result pre="a function of EdAP (filled circle and solid line) or" exact="oseltamivir" post="carboxylate (open square and dashed line) concentrations, as indicated."/>
</results>
